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Background
Five artemisinin combination therapies (ACTs) are cur-
rently recommended for treatment of uncomplicated
malaria in Africa. Whilst the artemisinin component has a
short half-life, the partner drugs give rise to differing dura-
tions of post-treatment prophylaxis, protecting from
re-infection and reducing transmission. We compared the
duration of post-treatment prophylaxis of artemether-
lumefantrine (AL), dihydroartemisinin-piperaquine (DHA-
PPQ) and artemisinine-amodiaquine (AS-AQ).
Materials and methods
We pooled the results from analyses of 6 trials (1651 indi-
viduals) of AL versus DHA-PPQ and from 18 trials (5060
individuals) of AL versus AS-AQ. The time to re-infection
after treatment was used to estimate the duration of post-
treatment protection accounting for the variation in trans-
mission intensity between settings. This duration was then
used in a mathematical model of malaria transmission to
estimate the comparative public health impact of each
drug used for 1st-line treatment in low, medium and high
transmission settings.
Results
We estimated a mean duration of post-treatment protec-
tion of 10.7 days (95% CI: 10.2-11.2) and 13.8 days (95%
CI: 10.2-22.8) for AL from the two analyses, 29.4 days
(95% CI: 16.4-48.8) for DHA-PPQ, and 11.8 days (95% CI:
11.0-12.5) for ASAQ. There was no substantial difference
in the public health impact of using AL versus AS-AQ.
Use of DHA-PPQ for 1st-line treatment averted 8.3 addi-
tional cases per 1,000 people (0.8% of all cases) over
5 years compared to AL or AS-AQ. This protective effect
was stronger in areas of high transmission as well as in
seasonal settings.
Conclusions
While it is important to maintain a diverse set of first-line
treatments for uncomplicated malaria, our results suggest
that partner drugs with a longer half-life could be benefi-
cial in reducing repeat episodes and onward transmission,
particularly in high and seasonal transmission areas.
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